Brainstorm Cell Therapeutics Newsroom

BrainStorm Issues 2024 Letter to Shareholders

PR NewswireDec 30, 2024 08:00 ET

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)

TipRanksDec 15, 2024 10:50 ET · Ratings

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

PR NewswireDec 9, 2024 07:00 ET

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

PR NewswireDec 3, 2024 07:00 ET

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

PR NewswireDec 2, 2024 07:00 ET

Express News | Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

BenzingaNov 14, 2024 17:23 ET

Brainstorm Cell Therapeutics | 8-K: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

SECNov 14, 2024 16:51 ET

Brainstorm Cell Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 14, 2024 16:46 ET · Announcements

Brainstorm Cell Therptcs 3Q Loss $2.71M >BCLI

Dow JonesNov 14, 2024 16:41 ET

Brainstorm Cell Therptcs 3Q Loss/Shr 51c >BCLI

Dow JonesNov 14, 2024 16:41 ET

Express News | Brainstorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

ReutersNov 14, 2024 16:30 ET

Press Release: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesNov 14, 2024 16:30 ET

Brainstorm Cell Therapeutics and Pluri Shares Are Trading Higher After the Companies Entered Into a Memorandum of Understanding to Manufacture NurOwn for a Phase 3b Trial in Amyotrophic Lateral Sclerosis.

BenzingaNov 11, 2024 08:27 ET

Express News | Brainstorm Cell Therapeutics and Pluri Partner to Support Nurown® Phase 3B Trial Manufacturing

ReutersNov 11, 2024 06:00 ET

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing

PR NewswireNov 11, 2024 06:00 ET

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating

Moomoo NewsOct 30, 2024 11:31 ET · Ratings

Express News | Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

ReutersOct 30, 2024 06:00 ET

BrainStorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

PR NewswireOct 30, 2024 06:00 ET

Express News | BrainStorm Cell Therapeutics Announced The Presentation Of Two Posters Featuring Nurown (MSC-NTF0 Or Debamestrocel) At The 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium Meeting

BenzingaOct 28, 2024 06:02 ET

BrainStorm Cell Therapeutics Presented Positive Survival Data From NurOwn Expanded Access Program at 2024 Annual NEALS Meeting

PR NewswireOct 28, 2024 06:00 ET